<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reflux <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (RO) and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BO) can cause esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (OAC) </plain></SENT>
<SENT sid="1" pm="."><plain>The esophageal mucosa in the RO-BO-OAC cascade is chronically exposed to <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-esophageal reflux</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Epidermal growth factor (EGF) has an important role in the protection and repair of mucosal damage, and non-physiologic levels are associated with <z:e sem="disease" ids="C0017185" disease_type="Neoplastic Process" abbrv="">gastrointestinal tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The aim is to determine the functional effect of EGF gene polymorphisms on RO, BO and OAC development </plain></SENT>
<SENT sid="4" pm="."><plain>A cohort of 871 unrelated Dutch Caucasians consisted of 198 healthy controls, 298 RO patients, 246 BO patients and 129 OAC patients </plain></SENT>
<SENT sid="5" pm="."><plain>The frequency of the EGF-production-associated 5'UTR A+61G polymorphism was determined in these four groups </plain></SENT>
<SENT sid="6" pm="."><plain>EGF immunohistochemistry was performed on BO biopsies </plain></SENT>
<SENT sid="7" pm="."><plain>EGF expression was significantly lower in the G/G genotype compared with the A/G (P=0.008) and A/A (P=0.002) group </plain></SENT>
<SENT sid="8" pm="."><plain>The G/G genotype was significantly more prevalent in RO (odds ratios (OR)=2.6; 95% confidence intervals (95% CI): 1.3-5.2), BO (OR=3.0; 95% CI: 1.5-6.2) and OAC (OR=4.1; 95% CI: 1.8-9.7) than in controls </plain></SENT>
<SENT sid="9" pm="."><plain>The G allele is associated with reduced EGF expression and increased risk for RO, BO and OAC development </plain></SENT>
<SENT sid="10" pm="."><plain>This indicates that reduced mucosal protection resulting from genetically decreased EGF expression enhances <z:e sem="disease" ids="C0014859" disease_type="Neoplastic Process" abbrv="">esophageal tumor</z:e> development </plain></SENT>
</text></document>